Selected article for: "concentration range and protein concentration"

Title: 2018 ACVIM Forum Research Abstract Program: Seattle, Washington, June 14 - 15, 2018
  • Document date: 2018_10_25
  • ID: 60ceejq1_367
    Snippet: Subsequently, they received immunosuppressive therapy within 2 months after the surgery due to recurrence of the lesion (n = 2) or based on the veterinarians'; decision (n = 2); the other 7 dogs were initially treated with immunosuppressive drugs. As a result, all dogs received immunosuppressive therapy with prednisolone (1-3 mg/kg/ day) and/or cyclosporine (5-6 mg/kg/day). After the initiation of immunosuppression, clinical signs were resolved a.....
    Document: Subsequently, they received immunosuppressive therapy within 2 months after the surgery due to recurrence of the lesion (n = 2) or based on the veterinarians'; decision (n = 2); the other 7 dogs were initially treated with immunosuppressive drugs. As a result, all dogs received immunosuppressive therapy with prednisolone (1-3 mg/kg/ day) and/or cyclosporine (5-6 mg/kg/day). After the initiation of immunosuppression, clinical signs were resolved and serum C-reactive protein concentration decreased to the reference range in all dogs within 2 months. Nine of the 11 dogs showed recurrence of the lesion when prednisolone was tapered (median duration from the initiation of immunosuppression: 55 days, range: 14-394 days); they responded well to re-induction of immunosuppression with higher-dose prednisolone (2-4 mg/kg/day) or with addition of cyclosporine or azathioprine. Median follow-up period was 462 days (range, 28-2,343 days), and 3 dogs died at 40, 322, and 1,450 days after initial presentation.

    Search related documents:
    Co phrase search for related documents
    • azathioprine cyclosporine and immunosuppressive therapy: 1
    • clinical sign and follow period: 1
    • clinical sign and high dose: 1, 2, 3
    • clinical sign and immunosuppressive therapy: 1
    • clinical sign and initial presentation: 1, 2
    • clinical sign and median duration: 1, 2
    • clinical sign and reference range: 1
    • dog reference range and reference range: 1, 2
    • follow period and high dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • follow period and immunosuppressive therapy: 1, 2, 3, 4
    • follow period and initial presentation: 1, 2, 3, 4, 5, 6
    • follow period and lesion recurrence: 1
    • follow period and median duration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • follow period and median follow period: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • follow period and protein concentration: 1